Drug Trial Radar · NCT06051409
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
Aug 31, 2023
Primary completion
Dec 31, 2027
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- Ascentage Pharma Group Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Guangzhou Healthquest Pharma Co., Ltd
- First posted
- Sep 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of olverembatinib combined with chemotherapy versus investigator's choice of tyrosine kinase inhibitor (TKI) combined with chemotherapy in subjects with newly-diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).
Conditions
- Ph+ ALL
- Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Interventions
OlverembatinibDrug
Oral (PO) once every other day (QOD).
Investigator's choice of TKIDrug
Oral (PO) once daily (QD).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Minimal Residual Disease Negative CR RateTime frame: Cycle 1 to Cycle 3 (each cycle is 28 days)
Locations
90 sites in 12 countries. Site status is shown where the registry gives one.
Ascentage Investigative Site #1044
Birmingham, Alabama · Not yet recruiting
Ascentage Investigative Site #1062
Duarte, California · Not yet recruiting
Ascentage Investigative Site #1134
Los Angeles, California · Not yet recruiting
Ascentage Investigative Site #1059
Los Angeles, California · Not yet recruiting
Ascentage Investigative Site #1142
Miami, Florida · Not yet recruiting
Ascentage Investigative Site #1045
Augusta, Georgia · Not yet recruiting
Ascentage Investigative Site #1158
Indianapolis, Indiana · Not yet recruiting
Ascentage Investigative Site #1069
Indianapolis, Indiana · Not yet recruiting
Ascentage Investigative Site #1084
Lexington, Kentucky · Not yet recruiting
Ascentage Investigative Site #1064
Hackensack, New Jersey · Not yet recruiting
Ascentage Investigative Site #1098
New Brunswick, New Jersey · Not yet recruiting
Ascentage Investigative Site #1160
Stony Brook, New York · Not yet recruiting
Ascentage Investigative Site #1151
The Bronx, New York · Not yet recruiting
Ascentage Investigative Site #1501
Houston, Texas · Not yet recruiting
Ascentage Investigative Site #1806
Seattle, Washington · Not yet recruiting
Ascentage Investigative Site #1155
Morgantown, West Virginia · Not yet recruiting
Royal North Shore Hospital
St Leonards, New South Wales, Australia · Active not recruiting
Royal Adelaide Hospital
Adelaide, South Australia, Australia · Active not recruiting
Alfred Health
Melbourne, Victoria, Australia · Active not recruiting
Royal Perth Hospital
Perth, Washington, Australia · Active not recruiting
The First Affiliated Hospital of Bengbu Medical School
Bengbu, Anhui, China · Not yet recruiting
Xinqiao Hospital of Army Medical University
Chongqing, Chongqing Municipality, China · Recruiting
Guangdong Province People's Hospital
Guangdong, Guangzhou, China · Recruiting
Nanfang Hospital of Southern Medical University
Guangdong, Guangzhou, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Wuhan Union Hospital of Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
The First Affiliated Hospital of Suzhou University
Suzhou, Jiangsu, China · Recruiting
Shanghai Jiao Tong University School of Medicine Ruijin Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Institute of Blood Transfusion of Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China · Recruiting
Ascentage Investigative Site #8647
Brno, Czechia · Not yet recruiting
Ascentage Investigative Site #6305
Hradec Králové, Czechia · Not yet recruiting
Ascentage Investigative Site #6304
Ostrava, Czechia · Not yet recruiting
Ascentage Investigative Site #6302
Prague, Czechia · Not yet recruiting
Ascentage Investigative Site #6309
Prague, Czechia · Not yet recruiting
Ascentage Investigative Site #5020
Le Chesnay, France · Not yet recruiting
Ascentage Investigative Site #5021
Lyon, France · Not yet recruiting
Ascentage Investigative Site #5013
Nantes, France · Not yet recruiting
Ascentage Investigative Site #5025
Nice, France · Not yet recruiting
Ascentage Investigative Site #5019
Pessac, France · Not yet recruiting
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.